Point-of-care cell therapy manufacturing; it’s not for everyone - Journal of Translational Medicine

▤ Summary

The article examines the rise of point-of-care and decentralized manufacturing for cell therapies, especially CAR T-cells and TILs. It explains that automated instruments and GMP reagents make local production technically feasible for academic centers. It also stresses that regulatory compliance, quality management, and harmonized testing create major challenges for multi-site manufacturing. The article concludes that point-of-care manufacturing may help in some cases, but many academic centers should carefully assess the costs and complexity before investing.

▦ Linked Companies